Completed PHASE2 INTERVENTIONAL 1-arm NCT01077466

Natalizumab Treatment of Progressive Multiple Sclerosis (NAPMS)

Sponsor: Biogen

Conditions Primary Progressive Multiple Sclerosis Secondary Progressive Multiple Sclerosis

Interventions Natalizumab

Updated 5 times since 2017 Last updated: Feb 15, 2012 Started: Mar 31, 2010 Primary completion: Jan 31, 2012 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Primary Progressive Multiple Sclerosis and Secondary Progressive Multiple Sclerosis, this trial is completed. The trial is conducted by Biogen and has accumulated 5 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biogen
Copenhagen University Hospital, Hvidovre
Rigshospitalet, Denmark
Signifikans ApS
University of Copenhagen

Data source: Rigshospitalet, Denmark

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Copenhagen, Denmark